Skip to main content
Erschienen in: Drugs & Aging 4/2000

01.10.2000 | Disease Management

Chemotherapy-Induced Oral Mucositis

Prevention and Management

verfasst von: Dr Jennifer J. Knox, Anitasha L. V. Puodziunas, Ronald Feld

Erschienen in: Drugs & Aging | Ausgabe 4/2000

Einloggen, um Zugang zu erhalten

Abstract

Oral mucositis is a frequent and potentially severe complication of chemotherapy which has a considerable impact on patient quality of life. While the management of other chemotherapy-related toxicities has improved, the incidence of mucositis is increasing. A critical review of the literature published between 1985 and 1999 reveals very few strategies or agents with proven efficacy, leaving few recommendations for the standard care in the prevention and treatment of mucositis at this time. Recommendations that can be made include: reducing patient risk factors, implementing proven preventative interventions such as utilising oral ice chips with fluorouracil chemotherapy, and optimising supportive care practices individualised to the patients’ needs and symptoms. Progress in understanding the pathophysiology of mucositis at the molecular level has led to the evaluation of a number of new investigational agents, specifically those directed to the epithelial mucosa, such as mitogens and epithelial growth factors. These appear to be very promising in preclinical studies. Randomised clinical trials with these agents may finally demonstrate an impact on the clinical practice of mucositis management in the coming years.
Literatur
1.
Zurück zum Zitat Rubenstein EB. Evaluating cost-effectiveness in outpatient management of medical complications in cancer patients. Curr Opin Oncol 1998; 10: 297–301PubMedCrossRef Rubenstein EB. Evaluating cost-effectiveness in outpatient management of medical complications in cancer patients. Curr Opin Oncol 1998; 10: 297–301PubMedCrossRef
2.
Zurück zum Zitat Sonis ST, Sonis AL, Liekerman A. Oral complications in patients receiving treatment for malignancies other than the head and neck. J Am Dent Assoc 1979; 97: 468–72 Sonis ST, Sonis AL, Liekerman A. Oral complications in patients receiving treatment for malignancies other than the head and neck. J Am Dent Assoc 1979; 97: 468–72
3.
Zurück zum Zitat Mahood DJ, Dose AM, Loprinzi CL, et al. Inhibition of fluoro-uracil-induced stomatitis by oral cryotherapy. J Clin Oncol 1991; 9: 449–52PubMed Mahood DJ, Dose AM, Loprinzi CL, et al. Inhibition of fluoro-uracil-induced stomatitis by oral cryotherapy. J Clin Oncol 1991; 9: 449–52PubMed
4.
Zurück zum Zitat Loprinzi CL, Dose AM. Studies on the prevention of 5-fluorouracil-induced oral mucositis. NCI Monogr 1990; 9: 93–4PubMed Loprinzi CL, Dose AM. Studies on the prevention of 5-fluorouracil-induced oral mucositis. NCI Monogr 1990; 9: 93–4PubMed
5.
Zurück zum Zitat Woo SB, Sonis ST, Monopoli MM, et al. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 1993; 72: 1612–7PubMedCrossRef Woo SB, Sonis ST, Monopoli MM, et al. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 1993; 72: 1612–7PubMedCrossRef
6.
Zurück zum Zitat Dodd MJ, Facione NC, Dibble SH, et al. Comparison of methods to determine the prevalence and nature of oral mucositis. Cancer Pract 1996; 4(6): 312–8PubMed Dodd MJ, Facione NC, Dibble SH, et al. Comparison of methods to determine the prevalence and nature of oral mucositis. Cancer Pract 1996; 4(6): 312–8PubMed
7.
Zurück zum Zitat McCarthy GM, Awde JD, Gtardi H, et al. Risk factors associated with mucositis in cancer patients receiving 5-FU. Oral Oncol 1998; 34: 484–90PubMedCrossRef McCarthy GM, Awde JD, Gtardi H, et al. Risk factors associated with mucositis in cancer patients receiving 5-FU. Oral Oncol 1998; 34: 484–90PubMedCrossRef
8.
Zurück zum Zitat Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 1998; 34: 39–43PubMedCrossRef Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 1998; 34: 39–43PubMedCrossRef
9.
Zurück zum Zitat Sonis S, Tracey C, Shklar G, et al. An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Pathol 1990; 69: 437–43PubMedCrossRef Sonis S, Tracey C, Shklar G, et al. An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Pathol 1990; 69: 437–43PubMedCrossRef
10.
Zurück zum Zitat Porta C, Moroni M, Nastasi G. Allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis. Am J Clin Oncol 1994; 17: 246–7PubMedCrossRef Porta C, Moroni M, Nastasi G. Allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis. Am J Clin Oncol 1994; 17: 246–7PubMedCrossRef
11.
Zurück zum Zitat Loprinzi CL, Cianflone SG, Dose AM, et al. A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-florouracil-induced stomatitis. Cancer 1990; 65: 1879–82PubMedCrossRef Loprinzi CL, Cianflone SG, Dose AM, et al. A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-florouracil-induced stomatitis. Cancer 1990; 65: 1879–82PubMedCrossRef
12.
Zurück zum Zitat Levi F, Zidani R, Missel JL. Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997; 350: 681–6PubMedCrossRef Levi F, Zidani R, Missel JL. Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997; 350: 681–6PubMedCrossRef
13.
Zurück zum Zitat Cascinu S, Fedeli A, Fedeli SL, et al. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. Eur J Cancer B Oral Oncol 1994; 30B: 234–6PubMedCrossRef Cascinu S, Fedeli A, Fedeli SL, et al. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. Eur J Cancer B Oral Oncol 1994; 30B: 234–6PubMedCrossRef
14.
Zurück zum Zitat Sato A, Kumagai S, Sakaki K, et al. Inhibition of 5-fluorouracil-cisplatin-induced stomatitis by oral cryotherapy: use of an ice-bar containing fibrinolysin and deoxyribonuclease combine (Elase) [in Japanese]. Gan To Kagaku Ryoho 1997; 24: 1135–9PubMed Sato A, Kumagai S, Sakaki K, et al. Inhibition of 5-fluorouracil-cisplatin-induced stomatitis by oral cryotherapy: use of an ice-bar containing fibrinolysin and deoxyribonuclease combine (Elase) [in Japanese]. Gan To Kagaku Ryoho 1997; 24: 1135–9PubMed
15.
Zurück zum Zitat Rocke LK, Loprinzi CL, Lee JK, et al. A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil related stomatitis. Cancer 1993; 72: 2234–8PubMedCrossRef Rocke LK, Loprinzi CL, Lee JK, et al. A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil related stomatitis. Cancer 1993; 72: 2234–8PubMedCrossRef
16.
Zurück zum Zitat Wolfrom C, Hartmann R, Fengler R, et al. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia. J Clin Oncol 1993; 11:827–33PubMed Wolfrom C, Hartmann R, Fengler R, et al. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia. J Clin Oncol 1993; 11:827–33PubMed
17.
Zurück zum Zitat Ahmed T, Engelking C, Szalyga J, et al. Propantheline prevention of mucositis from etoposide. Bone Marrow Transplant 1993; 12: 131–2PubMed Ahmed T, Engelking C, Szalyga J, et al. Propantheline prevention of mucositis from etoposide. Bone Marrow Transplant 1993; 12: 131–2PubMed
18.
Zurück zum Zitat Ackland SP, Schilsky RL. High-dose methotrexate: a critical re-appraisal. J Clin Oncol 1987; 5: 2017–31PubMed Ackland SP, Schilsky RL. High-dose methotrexate: a critical re-appraisal. J Clin Oncol 1987; 5: 2017–31PubMed
19.
Zurück zum Zitat Oliff A, Bleyer WA, Poplock DG. Methotrexate-induced oral mucositis and salivary methotrexate concentrations. Cancer Chemother Pharmacol 1979; 2: 225–5PubMedCrossRef Oliff A, Bleyer WA, Poplock DG. Methotrexate-induced oral mucositis and salivary methotrexate concentrations. Cancer Chemother Pharmacol 1979; 2: 225–5PubMedCrossRef
20.
Zurück zum Zitat Mills ED. The modifying effect of beta-carotene on radiation and chemotherapy-induced oral mucositis. Br J Cancer 1988; 57: 416–7PubMedCrossRef Mills ED. The modifying effect of beta-carotene on radiation and chemotherapy-induced oral mucositis. Br J Cancer 1988; 57: 416–7PubMedCrossRef
21.
Zurück zum Zitat Labar B, Mrsic M, Pavletic Z, et al. Prostaglandin E2 for prophylaxis of oral mucositis following BMT. Bone Marrow Transplant 1993; 11: 379–82PubMed Labar B, Mrsic M, Pavletic Z, et al. Prostaglandin E2 for prophylaxis of oral mucositis following BMT. Bone Marrow Transplant 1993; 11: 379–82PubMed
22.
Zurück zum Zitat Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial. Blood 1992; 80: 1430–6PubMed Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial. Blood 1992; 80: 1430–6PubMed
23.
Zurück zum Zitat Katano M, Nakamura M, Matsuo T, et al. Effect of granulocyte colony-stimulating factor (G-CSF) on chemotherapy-induced oral mucositis. Surg Today 1995; 25: 202–6PubMedCrossRef Katano M, Nakamura M, Matsuo T, et al. Effect of granulocyte colony-stimulating factor (G-CSF) on chemotherapy-induced oral mucositis. Surg Today 1995; 25: 202–6PubMedCrossRef
24.
Zurück zum Zitat Karthaus M, Rosenthal C, Huebner G, et al. Effect of topical oral G-CSF on oral mucositis: a randomized placebo-controlled trial. Bone Marrow Transplant 1998; 22: 781–5PubMedCrossRef Karthaus M, Rosenthal C, Huebner G, et al. Effect of topical oral G-CSF on oral mucositis: a randomized placebo-controlled trial. Bone Marrow Transplant 1998; 22: 781–5PubMedCrossRef
25.
Zurück zum Zitat Chi KH, Chen CH, Chan WK, et al. Effect of granulocyte-mac-rophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 1995; 13: 2620–8PubMed Chi KH, Chen CH, Chan WK, et al. Effect of granulocyte-mac-rophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 1995; 13: 2620–8PubMed
26.
Zurück zum Zitat Nemunaitis J, Rosenfeld CS, Ash R, et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 949–54PubMed Nemunaitis J, Rosenfeld CS, Ash R, et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 949–54PubMed
27.
Zurück zum Zitat Jebb SA, Osborne RJ, Maughan TS, et al. 5-Flourouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation. Br J Cancer 1994; 70: 732–5PubMedCrossRef Jebb SA, Osborne RJ, Maughan TS, et al. 5-Flourouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation. Br J Cancer 1994; 70: 732–5PubMedCrossRef
28.
Zurück zum Zitat Duenas-Gonzalez A, Sobrevilla-Calvo P, Frias-Medivil M, et al. Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study. Bone Marrow Transplant 1996; 17: 809–12PubMed Duenas-Gonzalez A, Sobrevilla-Calvo P, Frias-Medivil M, et al. Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study. Bone Marrow Transplant 1996; 17: 809–12PubMed
29.
Zurück zum Zitat Cohen G, Elad S, Or R, et al. The use of tretinoin as oral mucositis prophylaxis in bone marrow transplantation patients: a preliminary study. Oral Dis 1997; 3: 243–6PubMedCrossRef Cohen G, Elad S, Or R, et al. The use of tretinoin as oral mucositis prophylaxis in bone marrow transplantation patients: a preliminary study. Oral Dis 1997; 3: 243–6PubMedCrossRef
30.
Zurück zum Zitat Weite K, Zadler C, Reiter A, et al. Differential effects of GMCSF in children with severe congenital neutropenia. Blood 1990; 75: 1056–63 Weite K, Zadler C, Reiter A, et al. Differential effects of GMCSF in children with severe congenital neutropenia. Blood 1990; 75: 1056–63
31.
Zurück zum Zitat Wilkes JD. Prevention and treatment of oral mucositis following cancer chemotherapy. Semin Oncol 1998; 25(5): 538–51PubMed Wilkes JD. Prevention and treatment of oral mucositis following cancer chemotherapy. Semin Oncol 1998; 25(5): 538–51PubMed
32.
Zurück zum Zitat Dedhar S, Gabomy L, Gallaway P, et al. Human GM-CSF is a growth factor active on a variety of cell types of non-hemato-poietic origin. Proc Natl Acad Sci U S A 1988; 85: 9253–7PubMedCrossRef Dedhar S, Gabomy L, Gallaway P, et al. Human GM-CSF is a growth factor active on a variety of cell types of non-hemato-poietic origin. Proc Natl Acad Sci U S A 1988; 85: 9253–7PubMedCrossRef
33.
Zurück zum Zitat Zaghlonl MS, Dorce MJ, Kallman RF, et al. Interleukin-1 increases thymidine labelling index of normal tissue of mice but not the tumor. Int J Radiat Oncol Biol Phys 1994; 29: 805–11CrossRef Zaghlonl MS, Dorce MJ, Kallman RF, et al. Interleukin-1 increases thymidine labelling index of normal tissue of mice but not the tumor. Int J Radiat Oncol Biol Phys 1994; 29: 805–11CrossRef
34.
Zurück zum Zitat Sonis S, Muska A, O’Brien J, et al. Alteration in the frequency, severity and duration of chemotherapy-induced mucosits in hamsters by interleukin-11. Eur J Cancer B Oral Oncol 1996; 31B: 261–6 Sonis S, Muska A, O’Brien J, et al. Alteration in the frequency, severity and duration of chemotherapy-induced mucosits in hamsters by interleukin-11. Eur J Cancer B Oral Oncol 1996; 31B: 261–6
35.
Zurück zum Zitat Sher CJ, Roberts JM. Inhibitors of mammalian Gl cyclin-dependent kinases. Genes Dev 1995; 9: 1149–63CrossRef Sher CJ, Roberts JM. Inhibitors of mammalian Gl cyclin-dependent kinases. Genes Dev 1995; 9: 1149–63CrossRef
36.
Zurück zum Zitat Spijkervet F, Sonis S. New frontiers in the management of chemotherapy-induced mucositis. Curr Opin Oncol 1998; 10Suppl. 1:523–7 Spijkervet F, Sonis S. New frontiers in the management of chemotherapy-induced mucositis. Curr Opin Oncol 1998; 10Suppl. 1:523–7
37.
Zurück zum Zitat Werner S. Keratinocyte growth factor: a unique player in epithelial repair processes. Cytokine Growth Factor Rev 1998; 9(2): 153–65PubMedCrossRef Werner S. Keratinocyte growth factor: a unique player in epithelial repair processes. Cytokine Growth Factor Rev 1998; 9(2): 153–65PubMedCrossRef
38.
Zurück zum Zitat Danilenko D. Pre-clinical and early clinical development of keratinocyte growth-factor. Toxicol Pathol 1999; 27(1): 64–71PubMedCrossRef Danilenko D. Pre-clinical and early clinical development of keratinocyte growth-factor. Toxicol Pathol 1999; 27(1): 64–71PubMedCrossRef
39.
Zurück zum Zitat Ferretti GA, Ash RC, Brown AT, et al. Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse. Bone Marrow Transplant 1988; 3: 483–93PubMed Ferretti GA, Ash RC, Brown AT, et al. Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse. Bone Marrow Transplant 1988; 3: 483–93PubMed
40.
Zurück zum Zitat Ferretti GA, Raybould TP, Brown AT, et al. Chlorhexidine prophylaxis for chemotherapy and radiotherapy-induced stomatitis: a randomized double-blind trial. Oral Surg Oral Med Oral Pathol 1990; 69: 331–8PubMedCrossRef Ferretti GA, Raybould TP, Brown AT, et al. Chlorhexidine prophylaxis for chemotherapy and radiotherapy-induced stomatitis: a randomized double-blind trial. Oral Surg Oral Med Oral Pathol 1990; 69: 331–8PubMedCrossRef
41.
Zurück zum Zitat Rutkauskas JS, Davis JW. Effects of chlorhexidine during im-munosuppressive chemotherapy: a prelimininary report. Oral Surg Oral Med Oral Pathol 1993; 76: 441–8PubMedCrossRef Rutkauskas JS, Davis JW. Effects of chlorhexidine during im-munosuppressive chemotherapy: a prelimininary report. Oral Surg Oral Med Oral Pathol 1993; 76: 441–8PubMedCrossRef
42.
Zurück zum Zitat Bubley GJ, Chapman B, Chapman SK, et al. Effect of acyclovir on radiation and chemotherapy-induced mouth lesions. Anti-microb Agents Chemother 1989; 33: 862–5CrossRef Bubley GJ, Chapman B, Chapman SK, et al. Effect of acyclovir on radiation and chemotherapy-induced mouth lesions. Anti-microb Agents Chemother 1989; 33: 862–5CrossRef
43.
Zurück zum Zitat Bergmann OJ, Mogensen SC, Ellermann-Eriksen S, et al. Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute mycloid leukemia: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 1997; 15: 2269–74PubMed Bergmann OJ, Mogensen SC, Ellermann-Eriksen S, et al. Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute mycloid leukemia: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 1997; 15: 2269–74PubMed
44.
Zurück zum Zitat Prada A, Chiesa F. Effects of benzydamine on the oral mucositis during antineoplastic radiotherapy and/or intra-arterial chemotherapy. Int J Tissue React 1987; 9: 115–9PubMed Prada A, Chiesa F. Effects of benzydamine on the oral mucositis during antineoplastic radiotherapy and/or intra-arterial chemotherapy. Int J Tissue React 1987; 9: 115–9PubMed
45.
Zurück zum Zitat Fidler P, Loprinzi CL, O’Fallon JR, et al. Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis. Cancer 1996; 77: 522–5PubMedCrossRef Fidler P, Loprinzi CL, O’Fallon JR, et al. Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis. Cancer 1996; 77: 522–5PubMedCrossRef
46.
Zurück zum Zitat Weisdorf DJ, Bostrom B, Raether D, et al. Oropharyngeal mucositis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouth rinse. Bone Marrow Transplant 1989; 4: 89–95PubMed Weisdorf DJ, Bostrom B, Raether D, et al. Oropharyngeal mucositis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouth rinse. Bone Marrow Transplant 1989; 4: 89–95PubMed
47.
Zurück zum Zitat Wahlin BY. Effects of chlorhexidine mouthrinse on oral heal in patients with acute leukemia. Oral Surg Oral Med Oral Pathol 1989; 68: 279–87PubMedCrossRef Wahlin BY. Effects of chlorhexidine mouthrinse on oral heal in patients with acute leukemia. Oral Surg Oral Med Oral Pathol 1989; 68: 279–87PubMedCrossRef
48.
Zurück zum Zitat Dodd MJ, Larson PJ, Dibble SL, et al. Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol Nurs Forum 1996; 23: 921–7PubMed Dodd MJ, Larson PJ, Dibble SL, et al. Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol Nurs Forum 1996; 23: 921–7PubMed
49.
Zurück zum Zitat Borowski B, Benhamou E, Pico JL, et al. Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: a randomized controlled trial comparing two protocols of dental care. Eur J Cancer B Oral Oncol 1994; 30B: 93–7PubMedCrossRef Borowski B, Benhamou E, Pico JL, et al. Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: a randomized controlled trial comparing two protocols of dental care. Eur J Cancer B Oral Oncol 1994; 30B: 93–7PubMedCrossRef
50.
Zurück zum Zitat Clift RA, Bianco JA, Appelbaum FR, et al. A randomized controlled trial of pentoxifylline for the prevention of regimenrelated toxicities in patients undergoing allogeneic marrow transplantation. Blood 1993; 82: 2025–30PubMed Clift RA, Bianco JA, Appelbaum FR, et al. A randomized controlled trial of pentoxifylline for the prevention of regimenrelated toxicities in patients undergoing allogeneic marrow transplantation. Blood 1993; 82: 2025–30PubMed
51.
Zurück zum Zitat Attal M, Huguet F, Rubie H, et al. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial. Blood 1993; 82: 732–6PubMed Attal M, Huguet F, Rubie H, et al. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial. Blood 1993; 82: 732–6PubMed
52.
Zurück zum Zitat Verdi CJ, Garewal HS, Koenig LM, et al. A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995; 80: 36–42PubMedCrossRef Verdi CJ, Garewal HS, Koenig LM, et al. A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995; 80: 36–42PubMedCrossRef
53.
Zurück zum Zitat Rahn R, Adamietz IA, Bõttcher FfD, et al. Povidone-iodine to prevent mucositis in patients during antineoplastic radio-chemotherapy. Dermatology 1997; 195Suppl. 2: 57–61PubMedCrossRef Rahn R, Adamietz IA, Bõttcher FfD, et al. Povidone-iodine to prevent mucositis in patients during antineoplastic radio-chemotherapy. Dermatology 1997; 195Suppl. 2: 57–61PubMedCrossRef
54.
Zurück zum Zitat Pfeiffer P, Madsen EL, Hansen O, et al. Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy: a randomized, double-blind cross-over study. Acta Oncol; 29: 171–3 Pfeiffer P, Madsen EL, Hansen O, et al. Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy: a randomized, double-blind cross-over study. Acta Oncol; 29: 171–3
55.
Zurück zum Zitat Shenep JL, Kalwinsky DK, Hutson PR, et al. Efficacy of ora sucralfate suspention in prevention and treatment of chemotherapy-induced mucositis. J Pediatr 1988; 113: 758–63PubMedCrossRef Shenep JL, Kalwinsky DK, Hutson PR, et al. Efficacy of ora sucralfate suspention in prevention and treatment of chemotherapy-induced mucositis. J Pediatr 1988; 113: 758–63PubMedCrossRef
56.
Zurück zum Zitat Loprinzi CL, Ghosh C, Camoriano J, et al. Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 1235–8PubMed Loprinzi CL, Ghosh C, Camoriano J, et al. Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 1235–8PubMed
57.
Zurück zum Zitat Malik IA, Moid I, Haq S, et al. A double-blind, placebo-controlled, randomized trial to evaluate the role of tetrachlor-odecaoxide in the management of chemotherapy-induced oral mucosits. J Pain Symptom Manage 1997; 14(2): 82–7PubMedCrossRef Malik IA, Moid I, Haq S, et al. A double-blind, placebo-controlled, randomized trial to evaluate the role of tetrachlor-odecaoxide in the management of chemotherapy-induced oral mucosits. J Pain Symptom Manage 1997; 14(2): 82–7PubMedCrossRef
58.
Zurück zum Zitat Wadleigh RG, Redman RS, Graham ML, et al. Vitamin E in the treatment of chemotherapy-induced mucositis. Am J Med 1992; 92: 481–4PubMedCrossRef Wadleigh RG, Redman RS, Graham ML, et al. Vitamin E in the treatment of chemotherapy-induced mucositis. Am J Med 1992; 92: 481–4PubMedCrossRef
59.
Zurück zum Zitat Lopez I, Goudou C, Ribrag V, et al. Treatment of mucositis with vitamine E prior to administration of myelosuppressive chemotherapy [in French]. Ann Med Interne Paris 1994; 52: 489–92 Lopez I, Goudou C, Ribrag V, et al. Treatment of mucositis with vitamine E prior to administration of myelosuppressive chemotherapy [in French]. Ann Med Interne Paris 1994; 52: 489–92
60.
Zurück zum Zitat Feld R. The role of surveillance cultures in patients likely to develop chemotherapy-induced mucositis. Support Care Cancer 1997; 5: 371–5PubMedCrossRef Feld R. The role of surveillance cultures in patients likely to develop chemotherapy-induced mucositis. Support Care Cancer 1997; 5: 371–5PubMedCrossRef
61.
Zurück zum Zitat Abdelaal AS, Barker DS, Fergusson MM. Treatment for irradiation-induced mucositis [letter]. Lancet 1989; I: 97CrossRef Abdelaal AS, Barker DS, Fergusson MM. Treatment for irradiation-induced mucositis [letter]. Lancet 1989; I: 97CrossRef
62.
Zurück zum Zitat Beck S. The impact of a systematic oral care protocol on stomatitis after chemotherap. Cancer Nurs 1979; 2: 185–99PubMedCrossRef Beck S. The impact of a systematic oral care protocol on stomatitis after chemotherap. Cancer Nurs 1979; 2: 185–99PubMedCrossRef
63.
Zurück zum Zitat Bondi E, Baroni C, Prete A, et al. Local antimicrobial therapy of oral mucositis in pediatric patients undergoing bone marrow transplantation. Oral Oncol 1997; 33: 322–6PubMedCrossRef Bondi E, Baroni C, Prete A, et al. Local antimicrobial therapy of oral mucositis in pediatric patients undergoing bone marrow transplantation. Oral Oncol 1997; 33: 322–6PubMedCrossRef
64.
Zurück zum Zitat Loprinzi CL, Gastineau DA, Foote RL. Oral complications. In: Abeloff MD, Armitage JO, Allen SL, et al., editors. Clinical oncology. New York (NY): Churchill Livingstone, 2000: 965–97 Loprinzi CL, Gastineau DA, Foote RL. Oral complications. In: Abeloff MD, Armitage JO, Allen SL, et al., editors. Clinical oncology. New York (NY): Churchill Livingstone, 2000: 965–97
Metadaten
Titel
Chemotherapy-Induced Oral Mucositis
Prevention and Management
verfasst von
Dr Jennifer J. Knox
Anitasha L. V. Puodziunas
Ronald Feld
Publikationsdatum
01.10.2000
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 4/2000
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200017040-00002

Weitere Artikel der Ausgabe 4/2000

Drugs & Aging 4/2000 Zur Ausgabe

Disease Management

Peritoneal Dialysis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.